Publications

Furuya T, Shapiro AB, Comita-Prevoir J, Kuenstner EJ, Zhang J, Ribe SD, Chen A, Hines D, Moussa SH, Carter NM, Sylvester MA, Romero JAC, Vega CV, Sacco MD, Chen Y, O’Donnell JP, Durand-Reville TF, Miller AA and Tommasi RA

N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay

Bioorganic and Medicinal Chemistry (2020)

Theuretzbacher U, Barbee L, Connolly K, Drusano G, Fernandes P, Hook E, Jerse A, O'Donnell J, Unemo M, Van Bambeke F, VanScoy B, Warn P, Werth BJ, Franceschi F, and Aliro E

Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea – challenges and opportunities

Clinical Microbiology and Infection (2020)

Durand-Réville RJ, Comita-Prevoir J, Zhang J, Wu X, May-Dracka T, Romero T, Wu F, Chen A, Shapiro AB, Carter N, McLeod S, Giacobbe R, Verheijen J, Lahiri S, Sacco M, Chen Y, O’Donnell J, Miller AA, Mueller JP, and Tommasi R

Discovery of an orally available diazabicyclooctane inhibitor (ETX0282) of class A, C and D serine β-lactamases

Journal of Medicinal Chemistry (2020)

Lickliter JD, Lawrence K, O’Donnell J, and Isaacs R

Safety, pharmacokinetics, and drug-drug interaction potential of intravenous durlobactam, a β-lactamase inhibitor, in healthy subjects

Antimicrobial Agents and Chemotherapy (2020)

Seifert H, Muller C, Stefanik D, Higgins PG, Miller A and Kresken M

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy (2020)

O’Donnell J, Tanudra A, Chen A, Hines D, Tommasi R, and Mueller J

Pharmacokinetic/pharmacodynamic determination and preclinical pharmacokinetics of the β-lactamase inhibitor ETX1317 and its orally available prodrug ETX0282

ACS Infectious Diseases (2020)

Bradford PA, Miller AA, O’Donnell J, and Mueller JP

Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates

ACS Infectious Diseases (2020)

Yang Q, Xu Y, Jia P, Zhu Y, Zhang J, Zhang G, Deng J, Hackel M, Bradford PA, and Reinhart H

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Journal of Antimicrobial Chemotherapy (2020)

Miller AA, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Tommasi R, and Muller JP

In vitro characterization of ETX1317, a broad-spectrum β-lactamase inhibitor that restores and enhances β-lactam activity against multi-drug-resistant Enterobacterales, including carbapenem-resistant strains

ACS Infectious Diseases (2020)

Sagan O, Yakubsevitch R, Yanev K, Fomkin R, Stone E, Hines D, O’Donnell J, Miller A, Isaacs R, and Srinivasan S

Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis

Antimicrobial Agents and Chemotherapy (2020)